Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A cross-sectional study of patients with and without substance use disorders in Community Mental Health Centres

Autor: Ruud Torleif, Waal Helge, Wüsthoff Linda E, Gråwe Rolf W

Publikováno v: BMC Psychiatry, Vol 11, Iss 1, p 93 (2011)

Abstract Background Epidemiological studies have consistently established high comorbidity between psychiatric disorders and substance use disorders (SUD). This comorbidity is even more prominent when psychiatric populations are studied. Previous stu

Externí odkaz: https://doaj.org/article/202827df43b04de28104f6348f453f1f

People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination.

Autor: Gainullin M; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; NEC OncoImmunity AS, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Federico L; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Røkke Osen J; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Chaban V; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Kared H; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Alirezaylavasani A; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Lund-Johansen F; Department of Immunology, Oslo University Hospital, Oslo, Norway.; ImmunoLingo Convergence Center, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Wildendahl G; Agency for Social and Welfare Services, Oslo, Norway., Jacobsen JA; Agency for Social and Welfare Services, Oslo, Norway., Sarwar Anjum H; Agency for Social and Welfare Services, Oslo, Norway., Stratford R; NEC OncoImmunity AS, Oslo, Norway., Tennøe S; NEC OncoImmunity AS, Oslo, Norway., Malone B; NEC OncoImmunity AS, Oslo, Norway., Clancy T; NEC OncoImmunity AS, Oslo, Norway., Vaage JT; Department of Immunology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Henriksen K; Agency for Social and Welfare Services, Oslo, Norway.; Student Health Services, University of Oslo, Oslo, Norway., Wüsthoff L; Unit for Clinical Research on Addictions, Oslo University Hospital, Oslo, Norway.; Norwegian Centre for Addiction Reasearch, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Munthe LA; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Jan 17; Vol. 14, pp. 1235210. Date of Electronic Publication: 2024 Jan 17 (Print Publication: 2023).